ST
BIS icon

Spot Trading’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Spot Trading’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,075
Closed -$640K – 3613
2015
Q3 		$640K Buy
+2,075
New +$490K 0.01% 1886

Other funds holding BIS

HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CAM
Chesapeake Asset Management New York $126M AUM 36.76% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
EM
Emancipation Management New York $22.4M AUM 18.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

Spot Trading's BIS Position: Q3 2014 in Review

Spot Trading sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q3 2014, closing a stake of 571 shares — an estimated $325K sold.

Spot Trading first reported a position in BIS in Q2 2014 and held it in 1 quarter. The position peaked at $325K in Q2 2014. 16 funds tracked by Wall St. Rank hold BIS as of Q3 2014.

  • Spot Trading reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q3 2014 after selling out during the quarter.
  • Spot Trading sold 571 ProShares UltraShort NASDAQ Biotechnology shares in Q3 2014, an estimated $325K.
  • Spot Trading first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2014 and held it in 1 quarter.
  • Spot Trading's ProShares UltraShort NASDAQ Biotechnology position peaked at $325K in Q2 2014.
  • 16 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q3 2014.

Based on Spot Trading's 13F filing for Q3 2014, filed 13 Nov 2014.